Key result
Genetic modifier alleles compensate for ion channel mutations in epileptic encephalopathies, offering new therapeutic targets.
Why the study?
Part of the large phenotypic variability in DEE patients with voltage-gated ion channel mutations may be explained by compensatory genetic modifier alleles, with therapeutic implications.
Answers are grounded in this paper and cite their sources.
Understanding the compensatory effects of genetic modifier alleles on voltage-gated ion channel mutations may inform future therapies for Developmental and Epileptic Encephalopathies.
Developmental and Epileptic Encephalopathies (DEEs) represent a clinically and genetically heterogeneous group of rare and severe epilepsies. DEEs commonly begin early in infancy with frequent seizures of various types associated with intellectual disability and leading to a neurodevelopmental delay or regression. Disease-causing genomic variants have been identified in numerous genes and are implicated in over 100 types of DEEs. In this context, genes encoding voltage-gated ion channels (VGCs) play a significant role, and part of the large phenotypic variability observed in DEE patients carrying VGC mutations could be explained by the presence of genetic modifier alleles that can compensate for these mutations. This review will focus on the current knowledge of the compensatory effect of DEE-associated voltage-gated ion channels and their therapeutic implications in DEE. We will enter into detailed considerations regarding the sodium channels SCN1A, SCN2A, and SCN8A; the potassium channels KCNA1, KCNQ2, and KCNT1; and the calcium channels CACNA1A and CACNA1G.
No takes yet. Share an insight, caveat, or question.
Shabani et al. (2024) conducted a review in Developmental and Epileptic Encephalopathies (DEEs). Voltage-gated ion channels (VGCs) compensatory effect was evaluated. Genetic modifier alleles can compensate for voltage-gated ion channel mutations in Developmental and Epileptic Encephalopathies, explaining phenotypic variability and offering therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: